je.st
news
Vivus - Flat Qsymia Scripts Point To Needed Shift
2015-03-02 21:52:57| Biotech - Topix.net
It is no secret that the Vivus's anti-obesity pill Qsymia have been pretty flat for over a year. If a flat sales trajectory is not troubling enough, the fact that Contrave from Orexigen is about to overtake Qsymia in just about 20 or 21 weeks should be a clear signal that a change is needed.
Tags: point
needed
flat
shift
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||